The FDA removed the clinical hold on Sarepta Therapeutics’ investigational Duchenne muscular dystrophy (DMD) therapy Tuesday after the company agreed to adjust its clinical trial protocols to include expanded monitoring of urine biomarkers.
https://www.pharmalive.com/wp-content/uploads/2021/02/FDA-Approves-Third-Sarepta-Treatment-For-Duchenne-Muscular-Dystrophy-BioSpace-2-26-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-09-06 14:42:112022-09-07 08:47:29FDA lifts hold on Sarepta’s DMD trial following protocol adjustments
